TGFBR1 and melanoma: Efficacy of ALK5 inhibition on a relatively immunogenic B16 melanoma model depends fully on CD8+ T cells because deletion of CD8+ T cells resulted in 100% loss in the efficacy of EW-7197 on tumour progression (Fig 6B and E).